<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530058</url>
  </required_header>
  <id_info>
    <org_study_id>237-2016</org_study_id>
    <nct_id>NCT04530058</nct_id>
  </id_info>
  <brief_title>The Effects of Metformin on Morbidity and Mortality in Elderly Patients</brief_title>
  <official_title>The Effects of Metformin on Morbidity and Mortality in Elderly Patients- a Prospective Randomized Control Trial (RCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Elderly patients have an increased susceptibility to burns and a substantial mortality that&#xD;
      has not significantly changed over the last three decades. Elderly burn patients not only&#xD;
      have an augmented response to burn but also express a prolonged hypermetabolic&#xD;
      response.Glucose metabolism with insulin resistance is a hypermetabolic response pathway that&#xD;
      profoundly affects post-burn outcomes. The aim if this study is to determine whether&#xD;
      metformin can improve morbidity and mortality in elderly burn patients. The investigators&#xD;
      hypothesize that metformin will improve clinical outcomes and mortality of elderly burn&#xD;
      patients by alleviating the complex inflammatory and hypermetabolic responses after burn.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Record mortality</measure>
    <time_frame>Acute hospitalization up to one year post burn.</time_frame>
    <description>Patient mortality will be recorded during hospitalization and outpatient follow-ups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Record the episodes of sepsis.</measure>
    <time_frame>daily until discharge (1-4 months post admission depending on severity of injury)]</time_frame>
    <description>Patients will be assessed daily for episodes of sepsis. The total number of episodes over the course of hospital stay will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Record episodes of infection.</measure>
    <time_frame>daily until discharge (1-4 months post admission depending on severity of injury)]</time_frame>
    <description>Patients will be assessed daily for episodes of infection. The total number of episodes over the course of hospital stay will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Record episodes of pneumonia.</measure>
    <time_frame>daily until discharge (1-4 months post admission depending on severity of injury)]</time_frame>
    <description>Patients will be assessed daily for episodes of infection. The total number of episodes over the course of hospital stay will be recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Organ function - ALP</measure>
    <time_frame>twice weekly until discharge (1-4 months post admission depending on severity of injury)]</time_frame>
    <description>Organ function will be assessed by measuring the biomarker: ALP (U/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Organ function - ALT</measure>
    <time_frame>twice weekly until discharge (1-4 months post admission depending on severity of injury)]</time_frame>
    <description>Organ function will be assessed by measuring the biomarker: ALT (U/L).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Organ function - Bilirubin</measure>
    <time_frame>twice weekly until discharge (1-4 months post admission depending on severity of injury)]</time_frame>
    <description>Organ function will be assessed by measuring the biomarker: bilirubin (umol).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Organ function - BUN</measure>
    <time_frame>twice weekly until discharge (1-4 months post admission depending on severity of injury)]</time_frame>
    <description>Organ function will be assessed by measuring the biomarker: blood urea nitrogen (BUN) (mmol).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Organ function - Creatinine</measure>
    <time_frame>twice weekly until discharge (1-4 months post admission depending on severity of injury)]</time_frame>
    <description>Organ function will be assessed by measuring the biomarker: creatinine (umol/L).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measures of steady-state resting energy expenditure (REE)</measure>
    <time_frame>weekly until discharge if a patient is intubated and ventilated (1-4 months post admission depending on severity of injury)]</time_frame>
    <description>Metabolic response to injury and illness can be studied by measuring steady-state resting energy expenditure. Hypermetabolism is used as a secondary endpoint as stress-induced diabetes is associated with inflammation and hypermetabolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perform oral glucose tolerance test</measure>
    <time_frame>once at discharge from hospital (1-4 months post admission depending on the severity of injury)]</time_frame>
    <description>Standard fasting oral glucose tolerance test with an intake of 75 g of glucose. Subsequent measurements (in mg/dl) of glucose in blood, insulin and c-peptide will be conducted over 2 hours.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 500 mg twice a day, administered orally or via gastric tube.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo twice a day, administered orally or via gastric tube.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 60 - 99 years of age.&#xD;
&#xD;
          2. ≥5% TBSA burn.&#xD;
&#xD;
          3. Admitted to burn center ≤ 120 hours post-burn injury.&#xD;
&#xD;
          4. At least one surgical intervention likely required.&#xD;
&#xD;
          5. Provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Death upon admission.&#xD;
&#xD;
          2. Decision not to treat due to burn injury severity.&#xD;
&#xD;
          3. Presence of anoxic brain injury that is not expected to result in complete recovery.&#xD;
&#xD;
          4. Pre-existing renal failure (eGFR is &lt; 30 mL/min).&#xD;
&#xD;
          5. Severe liver disease (Child-Pugh C).&#xD;
&#xD;
          6. Pre-existing insulin-dependent type II diabetes.&#xD;
&#xD;
          7. Clinical contraindication to give metformin.&#xD;
&#xD;
          8. Allergy to metformin or insulin.&#xD;
&#xD;
          9. History of lactic acidosis while receiving metformin treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc G Jeschke, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc G Jeschke, MD PhD</last_name>
    <phone>416-480-6703</phone>
    <email>marc.jeschke@sunnybrook.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc G. Jeschke, MD PhD</last_name>
      <phone>416-480-6703</phone>
    </contact>
    <investigator>
      <last_name>Marc G. Jeschke, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

